Zika Virus - Industry Response to Disease Outbreaks Case Study

Zika Virus - Industry Response to Disease Outbreaks Case Study



When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the pharmaceutical industry to develop interventions to curb these potential disasters. This case study analyzes how the industry responded to the Zika outbreak, and how it compares and contrasts to the current COVID-19 outbreak.

Compare and contrast the pharmaceutical industrys response to a previous outbreak (Zika) to that for COVID-19.

Scope

- Development landscape and industry response to outbreaks

Reasons to Buy

- Understand the global epidemiology of COVID-19
- Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
- Access an overview of the pipeline for therapeutics and vaccines
- Stay up to date on available efficacy data for pipeline-stage products
- View the clinical trials landscape by across key attributes
- Get up to speed on highlights in deal-making trends, particularly public-private partnerships
- Monitor top trends in social media coverage

1 Executive Summary
1.1 Report Scope
1.2 Navigate the COVID-19 Outbreak with GlobalData Pharmas COVID-19 Dashboard
1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators
2 Epidemiology
2.1 Epidemiology: Snapshot as of March 25, 2020
2.2 Epidemiology: Disease Trajectory as of March 25, 2020
2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
2.6 Epidemiology Forecast: United States
3 Pipeline Overview
3.1 Pipeline Therapeutics: Breakdown by Phase
3.2 Pipeline Therapeutics: Breakdown by Molecule Type
3.3 Pipeline Therapeutics: Breakdown by Type of Developer
3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
3.6 Pipeline Therapeutics: Currently Available Data
3.7 Pipeline Vaccines: Breakdown by Phase
3.8 Pipeline Vaccines: Breakdown by Developer Type
3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
Pipeline Overview
4.1 Pipeline Therapeutics: Breakdown by Phase
4.2 Pipeline Therapeutics: Breakdown by Molecule Type
4.3 Pipeline Therapeutics: Breakdown by Type of Developer
4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
4.5 Pipeline Therapeutics: Preclinical-Stage Candidates
4.6 Pipeline Therapeutics: Currently Available Data
4.7 Pipeline Vaccines: Breakdown by Phase
4.8 Pipeline Vaccines: Breakdown by Developer Type
4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
Clinical Trials
5.1 Clinical Trials: Breakdown by Phase
5.2 Clinical Trials for Therapeutics and Vaccines
5.3 Clinical Trials: Overview by Region
5.4 Clinical Trials for Therapeutics: Leading Sponsors
5.5 Clinical Trials: Leading Industry Sponsors
5.6 Trends in Trial Design
Deal-making Trends
6.1 Deal-making Trends
Social Media Trends
7.1 Key Twitter Chatter
7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve
Key Findings
8.1 Key Findings
Appendix
9.1 Sources
9.2 Methodology
9.3 About the Authors
About GlobalData
10.1 Contact Us

Zika Virus Infection - Pipeline Insight, 2021

DelveInsights, Zika Virus Infection - Pipeline Insight, 2021, report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug

USD 1500 View Report

Zika Virus Envelope Protein (E) - Drugs in Development, 2021

Zika Virus Envelope Protein (E) - Drugs in Development, 2021Zika Virus Envelope Protein (E) - Drugs in Development, 2021 provides in depth analysis on Zika Virus Envelope Protein (E) targeted

USD 3000 View Report

Zika Virus Infection - Pipeline Insight, 2021

DelveInsights, Zika Virus Infection - Pipeline Insight, 2021, report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug

USD 1500 View Report

Zika Virus Envelope Protein (E) - Drugs in Development, 2021

Zika Virus Envelope Protein (E) - Drugs in Development, 2021Zika Virus Envelope Protein (E) - Drugs in Development, 2021 provides in depth analysis on Zika Virus Envelope Protein (E) targeted

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available